A carregar...
Publicação
Effectiveness of the 2023 Autumn XBB.1.5 COVID-19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Study
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 189.29 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Background: After a period of low SARS- CoV-2 activity, viral circulation increased in Europe from May 2024, driven byimmune-evasive KP sublineages of the JN.1 variant. We estimated vaccine effectiveness (VE) of the XBB.1.5 dose administeredin autumn 2023 against COVID-19-related hospitalisations and deaths in individuals 65 years of age or older during this period.
Methods: We conducted a multi-country cohort study across six EU nations in the VEBIS-EHR network using linked electronichealth records. VE against COVID-19-related hospitalisation and death during June–August 2024 was estimated using Cox re-gression in a two-stage analysis, adjusting for demographics, comorbidities and prior vaccination history.
Results: Among individuals 65–79 and ≥ 80 years old, respectively, VE of the XBB.1.5 dose ≥ 6 months post administration was13% (95% CI: −12% to 33%) and 7% (95% CI: −7% to 19%) against hospitalisation and 39% (95% CI: −7% to 65%) and 3% (95% CI:−23% to 23%) against deaths.
Conclusions: XBB.1.5 vaccination provided minimal residual protection against severe COVID-19 outcomes among adults aged≥ 65 years more than 6 months after vaccination, during the summer 2024 period of increased SARS- CoV-2 activity.
Descrição
Palavras-chave
COVID-19 XBB.1.5 Electronic Health Records Vaccine Effectiveness VEBIS Infecções Respiratórias Estados de Saúde e de Doença
Contexto Educativo
Citação
Influenza Other Respir Viruses. 2025 Dec;19(12):e70198. doi: 10.1111/irv.70198
Editora
Wiley